IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chengliang, Gan, Gregory N., Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275499/
https://www.ncbi.nlm.nih.gov/pubmed/32503595
http://dx.doi.org/10.1186/s13045-020-00898-y
_version_ 1783542797383499776
author Huang, Chengliang
Gan, Gregory N.
Zhang, Jun
author_facet Huang, Chengliang
Gan, Gregory N.
Zhang, Jun
author_sort Huang, Chengliang
collection PubMed
description The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.
format Online
Article
Text
id pubmed-7275499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72754992020-06-08 IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer Huang, Chengliang Gan, Gregory N. Zhang, Jun J Hematol Oncol Letter to the Editor The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials. BioMed Central 2020-06-05 /pmc/articles/PMC7275499/ /pubmed/32503595 http://dx.doi.org/10.1186/s13045-020-00898-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Huang, Chengliang
Gan, Gregory N.
Zhang, Jun
IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title_full IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title_fullStr IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title_full_unstemmed IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title_short IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
title_sort impower, caspian, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275499/
https://www.ncbi.nlm.nih.gov/pubmed/32503595
http://dx.doi.org/10.1186/s13045-020-00898-y
work_keys_str_mv AT huangchengliang impowercaspianandmoreexploringtheoptimalfirstlineimmunotherapyforextensivestagesmallcelllungcancer
AT gangregoryn impowercaspianandmoreexploringtheoptimalfirstlineimmunotherapyforextensivestagesmallcelllungcancer
AT zhangjun impowercaspianandmoreexploringtheoptimalfirstlineimmunotherapyforextensivestagesmallcelllungcancer

Ejemplares similares